CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 1,420.0	$ 322.6
Trade receivables, net	2,696.3	2,075.8
Inventories, net	1,199.2	950.6
Prepaid expenses and other current assets	953.0	650.8
Deferred tax assets, net	727.2	193.3
Total current assets	6,995.7	4,193.1
Property, plant and equipment, net	1,351.4	1,310.5
Intangible assets, net	22,382.1	11,255.9
Goodwill	17,374.7	9,346.4
Deferred tax assets, net	114.6	54.0
Other long-term assets, net	236.1	167.4
Total assets	48,454.6	26,327.3
Current liabilities:
Accounts payable	476.8	398.0
Accrued and other current liabilities	3,293.5	2,179.4
Acquisition-related contingent consideration	161.6	141.8
Current portion of long-term debt	707.0	0.9
Deferred tax liabilities, net	11.6	10.7
Total current liabilities	4,650.5	2,730.8
Acquisition-related contingent consideration	600.2	167.0
Long-term debt	30,176.3	15,228.0
Pension and other benefit liabilities	221.9	239.8
Liabilities for uncertain tax positions	109.3	102.6
Deferred tax liabilities, net	6,022.6	2,227.5
Other long-term liabilities	209.1	197.1
Total liabilities	$ 41,989.9	$ 20,892.8
Commitments and contingencies
Equity
Common shares, no par value, unlimited shares authorized, 342,769,031 and 334,402,964 issued and outstanding at June 30, 2015 and December 31, 2014, respectively	$ 9,899.6	$ 8,349.2
Additional paid-in capital	244.6	243.9
Accumulated deficit	(2,338.5)	(2,365.0)
Accumulated other comprehensive loss	(1,463.4)	(915.9)
Total Valeant Pharmaceuticals International, Inc. shareholders’ equity	6,342.3	5,312.2
Noncontrolling interest	122.4	122.3
Total equity	6,464.7	5,434.5
Total liabilities and equity	$ 48,454.6	$ 26,327.3